Please Subscribe to get a daily link to Pat's blog via email


Your privacy is important to us. We will never spam you and keep your personal data secure.


4 06, 2015

ASCO NEWS: ARRY-520 (filanesib) missing in action?

Tags: , , |2 Comments

Reports about the promising and innovative new myeloma therapy, ARRY-520 (filanesib), were conspicuously absent at this year's American Society of Clinical Oncology (ASCO) meetings this year in Chicago. Many myeloma specialists are hopeful that filanesib will match or even exceed the headline making results revealed for  daratumumab at this year's annual event.  Yet the only

19 01, 2015

Update: ARRY-520

Tags: , , , |3 Comments

At the American Society of Hematology (ASH) meetings in San Francisco last December, I had a chance to sit down with Selena Rush, Director of Clinical Operations at Array Biopharma.  Array manufactures the promising new myeloma therapy, ARRY-520 (filanesib). I had two reasons to meet with Selena.  First, to get an update on ARRY-520; there

8 01, 2015

If this works out a lot of us may live longer…

Tags: , , , , , , |0 Comments

Our next, best shot: immunotherapy agents that attack CD38 proteins on the cell walls of multiple myeloma cells: Anti-CD38 antibodies poised to transform myeloma treatment By: PATRICE WENDLING, Oncology Practice Digital Network Jan 5, 2015 Vitals Key clinical point: The investigational anti-CD38 antibodies SAR650984 and daratumumab in combination with standard regimens were highly active in

10 01, 2014

Best of ASH (Part Three)

Tags: , , , |4 Comments

I have been remiss not passing along data from one of the hottest new therapies for multiple myeloma,  ARRY-520. I saved this press release from the drug's parent company, Array BioPharma, Inc, to post after the dust settled, post ASH.  Let's discuss on the other side:   Array BioPharma Provides Clinical Update On Filanesib (ARRY-520)

21 07, 2013

Multiple Myeloma News

Tags: , , , , , , , , |0 Comments

The myeloma world doesn't stop turning just because I"m out of town visiting my father.   Let's catch-up on a few important odds 'n ends today. First, I received an email from a reader, questioning the value of the Mayo Clinic retrospective study that Danny Parker and I reported on yesterday.  The issue: the study or

10 07, 2013

Updated 2013 edition, New Multiple Myeloma Therapies from a Patient’s Perspective, available NOW!

Tags: , , , |2 Comments

My updated 2013 edition of New Multiple Myeloma Therapies from a Patient's Perspective has just been published.  When I wrote the book less than a year ago, I knew things were changing quickly in myeloma research--and I knew that I would need to update the book periodically.  But who knew new drugs like ARRY-520 and

18 06, 2013

Missing in action at ASCO, ARRY-520 hot topic in Europe

Tags: , , , , , |9 Comments

Something was missing from this year's American Society of Clinical Oncology (ASCO) meetings in Chicago this year.  Conspicuously absent was any news about one of the most promising anti-myeloma drugs, ARRY-520.  Why?  Was there a problem with ARRY-520's trial data? Absolutely not!  It turns-out that decision makers at the company that is developing ARRY-520, Array

27 12, 2012

ARRY-520 and another pomalidomide study

Tags: , , |12 Comments

I haven't written much about ARRY-520, this year's rising myeloma star at ASH. ARRAY Biopharma is developing ARRY-520, a potent, selective KSP inhibitor; its mechanism of action is distinct from other drugs used to treat multiple myeloma.  I have written about it before and featured ARRY-520 a number of times on I attended an

13 10, 2011

Dr. Orlowski’s post-transplant therapy advice

Tags: , , , , , |7 Comments

Yesterday I wrote about how fortunate I was to have received second opinions--via email--from two well know, well respected mutliple myeloma experts. Today, let me share what Dr. Robert Orlowski, Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center in Houston, Texas, suggested I do after learning about

21 08, 2011

Carfilzomib, Elotuzumab, Panobinostat, Vorinostat And Arry520 All Show Promise In Late Stage Clinical Studies Against Multiple Myeloma

Tags: , , , , , , , , |0 Comments

Yesterday I wrote about three anti-myeloma clinical studies involving carfilzomib, elotuzumab and panobinostat. I referred to elotuzumab and panobinostat as promising "assisting type" drugs.  Also known as secondary or “helper” novel therapy agents, elotuzumab, panobinostat, vorinostat and/or ARRY520 are all showing promise working with primary novel therapy agents like thalidomide, Revlimid and Velcade. It is

6 12, 2010

Dr. Robert Orlowski From M.D. Anderson Previews Exciting, Positive New Therapy Data To Be Revealed At ASH

Tags: , , , , , , , |1 Comment

As promised, here is the final installment of my three part report on the IMF's ASH kick-off panel discussion Friday evening at the Peabody Hotel in Orlando:I have already written two articles about Friday evening’s IMF panel of experts program, Key Myeloma Questions for 2010: Latest Developments in Diagnosis, Prognosis and treatment.Let’s conclude with M.D.

6 12, 2010

Reflections Before Opening The Flood Gates Of Technical Multiple Myeloma Related Information From This Year’s ASH

Tags: , , , , , |1 Comment

I wanted to share my thoughts from ASH after a very busy weekend.  On our other daily site,, I am reporting about non-multiple myeloma related news from this year's meetings.  You can imagine how difficult it is to determine which studies are most significant when dealing with dozens and dozens of hematological cancers.  I